Marché mondial de la réduction des risques cardiovasculaires – Tendances et prévisions du secteur jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché de la réduction du risque cardiovasculaire devrait connaître une croissance rapide au cours de la période de prévision. Les maladies cardiovasculaires sont les principales causes de décès dans le monde. Les cardiopathies ischémiques sont responsables de 16 % de tous les décès dans le monde, selon les mises à jour 2020 de l'Organisation mondiale de la santé (OMS). Selon un article intitulé Heart failure (HF) in France, chronic heart failure therapy management and risk of heart decompensation in a real-life setting, environ un million de personnes en France seront touchées par l'IC ; près de 70 000 personnes mourront d'IC ​​et plus de 150 000 personnes seront hospitalisées malgré une gestion thérapeutique bien définie.

Français Data Bridge Market Research analyse que le marché de la réduction des risques cardiovasculaires était évalué à 71,96 milliards USD en 2021 et devrait atteindre 96,98 milliards USD d'ici 2029, enregistrant un TCAC de 3,80 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe Data Bridge Market Research comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

Les maladies cardiovasculaires (MCV) sont des maladies qui affectent le cœur et le système circulatoire. L'hypertension, les cardiopathies cérébrovasculaires, les maladies inflammatoires du cœur, les cardiopathies ischémiques et les cardiopathies rhumatismales sont quelques-unes des maladies cardiovasculaires les plus courantes. L'hypertension artérielle provoque une cardiopathie hypertensive.

Portée du rapport et segmentation du marché

Cardiovascular Risk Reduction Market Dynamics

Drivers

• Increasing prevalence of cardiovascular diseases

The rising prevalence of cardiovascular diseases is estimated to enhance the market's growth. According to World Health Organization (WHO), CVDs claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85 percent of these deaths.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cardiovascular risk reduction market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get cardiovascular disease, further estimated to enhance the market’s growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cardiovascular risk reduction market. Additionally, changing lifestyle of people and rising level of disposable income will result in the expansion of cardiovascular risk reduction market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cardiovascular risk reduction market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cardiovascular risk reduction market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cardiovascular risk reduction market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cardiovascular risk reduction market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiovascular risk reduction market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cardiovascular risk reduction market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cardiovascular Risk Reduction Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The cardiovascular risk reduction market was hampered by the supply chain slowness.

Global Cardiovascular Risk Reduction Market Scope

The cardiovascular risk reduction market is segmented on the basis of diseases, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases

• Hypertension
• Dyslipidemia
• Diabetes
• Others

Treatment

• Antiplatelet Agents
• Beta-Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cardiovascular Risk Reduction Market Regional Analysis/Insights

The cardiovascular risk reduction market is analysed and market size insights and trends are provided by country, diseases, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cardiovascular risk reduction market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the cardiovascular risk reduction market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market’s growth rate in this region.

La région Asie-Pacifique devrait connaître une croissance au cours de la période de prévision en raison du nombre croissant de fabricants de génériques dans cette région. De plus, le développement des infrastructures de santé et l'augmentation des initiatives gouvernementales propulseront davantage le taux de croissance du marché dans cette région.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché de la réduction des risques cardiovasculaires

Le paysage concurrentiel du marché de la réduction des risques cardiovasculaires fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la réduction des risques cardiovasculaires.

Certains des principaux acteurs opérant sur le marché de la réduction des risques cardiovasculaires sont :

• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Teva Pharmaceutical Industries Ltd. (Israël)
• Sanofi (France)
• Pfizer Inc. (États-Unis)
• GlaxoSmithKline plc (Royaume-Uni)
• Novartis SA (Suisse)
• Zydus Cadila (Inde)
• AstraZeneca (Royaume-Uni)
• Johnson & Johnson (États-Unis)
• Bayer AG (Allemagne)
• Sun Pharmaceutical Industries Ltd. (Inde)
• Société Bristol-Myers Squibb (États-Unis)
• Eli Lilly and Company (États-Unis)
• Cipla Inc. (États-Unis)
• Endo International plc (Irlande)
• Aurobindo Pharma (Inde)
• Lupin (Inde)
• Hikma Pharmaceuticals PLC (Royaume-Uni)

SKU-54416